Preparation method of traditional Chinese medicine compound and application in prevention and treatment of Alzheimer disease

Abstract

The invention discloses a preparation method of a traditional Chinese medicine compound and application in prevention and treatment of Alzheimer disease. The traditional Chinese medicine compound is composed of 180 parts of Ginkgo leaf, 180 parts of Radix Polygonum Multiflorum Preparata, 90 parts of glossy privet fruit, 90 parts of Salvia miltiorrhiza, 90 parts of in Eucommia ulmoides, 90 parts of Cyathula officinalis, and 60 parts of Uncaria tomentosa. The traditional Chinese medicine compound is prepared by the method of: subjecting the Ginkgo leaf, glossy privet fruit, Salvia miltiorrhiza and Uncaria tomentosa to heating reflux extraction by 30-95% ethanol 1-4 times, recovering ethanol from the extracted solution and conducting concentration to obtain an extract A; adding water into the Radix Polygonum Multiflorum Preparata, Eucommia ulmoides, and Cyathula officinalis to conduct decoction and extraction 1-4 times, concentrating the decocted solution and then performing alcohol precipitation, recovering ethanol from the alcohol precipitated solution and conducting concentration, thus obtaining an extract B; and drying the extract A and the extract B, taking the dry extracts, and adding appropriate auxiliary materials to prepare hard capsules, soft capsules, tablets and granules. The traditional Chinese medicine compound prepared by the method provided by the invention can significantly improve the treatment effect on various diseases caused by cerebral arteriosclerosis, and has preventive and therapeutic effects on Alzheimer disease.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine pharmacy, and more specifically relates to a preparation method of a traditional Chinese medicine compound and its application in preventing and treating senile dementia. Background technique [0002] The present invention is based on the composition disclosed in the patent application of "A Traditional Chinese Medicine for Treating Cerebral Arteriosclerosis" (patent application number: 200410045091.7, publication number: CN1596960A), according to the different characteristics of the active substances contained in the raw materials in the composition , a new process technology (referred to as the new process) created by using different extraction and preparation methods. The material basis of the drug prepared by the new process is similar to that obtained by the preparation method disclosed in the original patent application (referred to as the original process). There is a s...

AI Technical Summary

Problems solved by technology

Therefore, it is advisable to extract Uncaria sinensis with ethanol, and the original process uses water as a solvent for long-term extraction, and there are technical drawbacks

② The original process has increased unnecessary process steps, and the loss of materials and energy consumption is great: Ginkgo biloba, Ligustrum lucidum, and Salvia miltiorrhiza are extracted 3 times with 70% ethanol, and their active ingredients such as ginkgo leaf flavonoids, ginkgolides, Aranolic acid, danshensu, total salvianolic acid, tanshinone, cryptotanshinone and other water-soluble or fat-soluble active ingredients have been basically extracted, and only some macromolecular components such as starch and Ligustrum lucidum remain in the dregs. Polysaccharides, glycoproteins and other substances, of which only the polysaccharide components have certain physiological activity, and the medicinal residues are then extracted together with medicinal flavors such as Radix Polygoni Multiflori. Although part of the polysaccharide components of Ligustrum lucidum can be extracted, the water extract is concentrated and then extracted. After 60% ethanol precipitation, this part of polysaccharide is precipitated and removed, and the dregs are combined with other raw materials and extracted with water, which not only greatly increases the amount of ethanol during alcohol precipitation, but also greatly increases the extraction, organic solvent recovery, and concentration. Energy consumption also increases the dosage of medicines, but it is of no benefit to improve the quality and efficacy of medicines

③The amount of solvent extracted by the original process is seriously insufficient, and the transfer rate of active ingredients is low: the amount of ethanol used in the three alcohol extractions of Ginkgo biloba, Ligustrum lucidum, and Salvia miltiorrhiza is 4.2 times, 3.3 times, and 3.3 times the weight of the medicinal materials, respectively, and the medicinal residues and Polygonum multiflorum are twice as strong. The amount of water added in the second water extraction is 3.0 times and 2.3 times of the weight of the medicinal materials respectively. The medicinal materials on the surface of the solvent are inconsistent, resulting in uneven quality of each batch of medicines, seriously affecting the quality and efficacy of medicines

④ The original process mainly used oral liquid dosage forms, and the dosage forms were improperly selected: ginkgolides in ginkgo biloba, oleanolic acid in Ligustrum lucidum, total alkaloids in Uncaria uncaria, tanshinone and cryptotanshinone in Salvia miltiorrhiza, etc. Both are insoluble in water or insoluble in water. If it is made into an aqueous solution, most of the above ingredients will be lost during the process, and a small part of the remaining ingredients will also be precipitated during storage. The bottom of the bottle not only seriously affects the appearance quality, but also seriously affects the curative effect of the drug. Even adding a solubilizer to the aqueous solution cannot effectively solve the above problems, so this compound is not suitable for making an aqueous solution preparation

[0016] Aiming at the pathogenesis of AD, the drugs currently on the market for the treatment of Alzheimer's disease mainly include drugs that inhibit the formation and deposition of Aβ and cholinesterase inhibitors, followed by glutamate receptor antagonists, calcium ion antagonists, and scavenging agents. Free radical agents, antioxidant drugs, estrogen and other auxiliary therapeutic drugs, the above drugs can only partially relieve symptoms, have treatment limitations, cannot treat the disease as a whole, and have certain toxic and side effects. The experience of research and development and clinical application of dementia drugs has made researchers at home and abroad realize that the treatment of AD requires early diagnosis and multi-target therapy. researchers concern

Images